XML 40 R28.htm IDEA: XBRL DOCUMENT
v3.25.2

Segment Reporting (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2025
Segment Reporting [Abstract] |
Schedule of Segment Revenue, Loss and Significant Expenses | The following table is a summary of segment revenue, loss and our significant expenses (in thousands):
| Three Months Ended June 30, |  | Six Months Ended June 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Collaboration revenue | $ | 22,263 |  |  | $ | 10,971 |  |  | $ | 50,034 |  |  | $ | 18,150 |
Operating expenses: |  |  |  |  |  |  |
External R&D |  |  |  |  |  |  |
Rosnilimab | 15,614 |  |  | 12,926 |  |  | 30,639 |  |  | 22,965 |
ANB033 | 3,925 |  |  | 2,982 |  |  | 7,729 |  |  | 5,645 |
ANB101 | 2,040 |  |  | 544 |  |  | 3,521 |  |  | 944 |
ANB032 | 108 |  |  | 7,584 |  |  | 3,644 |  |  | 12,451 |
Imsidolimab | (967) |  |  | 1,867 |  |  | (1,156) |  |  | 6,363 |
Preclinical and other unallocated costs | 4,456 |  |  | 4,693 |  |  | 8,388 |  |  | 8,037 |
Total External R&D(1) | 25,176 |  |  | 30,596 |  |  | 52,765 |  |  | 56,405 |
Total Internal R&D(2) | 12,648 |  |  | 11,401 |  |  | 26,239 |  |  | 22,634 |
Total R&D | 37,824 |  |  | 41,997 |  |  | 79,004 |  |  | 79,039 |
External G&A(3) | 2,436 |  |  | 2,330 |  |  | 7,976 |  |  | 4,451 |
Internal G&A(2) | 8,173 |  |  | 6,965 |  |  | 16,763 |  |  | 17,182 |
Total G&A | 10,609 |  |  | 9,295 |  |  | 24,739 |  |  | 21,633 |
Total operating expenses | 48,433 |  |  | 51,292 |  |  | 103,743 |  |  | 100,672 |
Loss from operations | (26,170) |  |  | (40,321) |  |  | (53,709) |  |  | (82,522) |
Interest income | 3,654 |  |  | 4,623 |  |  | 8,067 |  |  | 9,207 |
Non-cash interest expense | (19,606) |  |  | (10,953) |  |  | (37,667) |  |  | (17,270) |
Other income (expense), net | 3,531 |  |  | — |  |  | 5,433 |  |  | (2) |
Total other expense, net | (12,421) |  |  | (6,330) |  |  | (24,167) |  |  | (8,065) |
Loss before income taxes | (38,591) |  |  | (46,651) |  |  | (77,876) |  |  | (90,587) |
Provision for income taxes | (39) |  |  | (9) |  |  | (83) |  |  | (9) |
Segment net loss | $ | (38,630) |  |  | $ | (46,660) |  |  | $ | (77,959) |  |  | $ | (90,596) |
(1) External R&D consists of costs associated with our research and development activities, including drug discovery efforts, preclinical and clinical development of our programs, manufacturing, and allocated facility-related costs. (2) Internal R&D and G&A consist of salaries and wages, stock-based compensation, recruiting and other employee benefits. (3) External G&A consists of general and administrative expenses including transaction costs, legal services, insurance, professional fees for auditing, tax, and market research, and allocated facility-related costs not otherwise included in research and development expenses.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration